Cargando…

Thrombotic Complications in Patients with Immune-Mediated Hemolysis

Autoimmune hemolytic anemias are rare and heterogeneous disorders characterized by hemolysis, which is a well-recognized risk factor for thrombosis. The most common immune-mediated anemias are represented by autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria, both associated with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capecchi, Marco, Ciavarella, Alessandro, Artoni, Andrea, Abbattista, Maria, Martinelli, Ida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073900/ https://www.ncbi.nlm.nih.gov/pubmed/33919638 http://dx.doi.org/10.3390/jcm10081764

Ejemplares similares

Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
por: Capecchi, Marco, et al.
Publicado: (2022)

Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura
por: Bichard, Christian, et al.
Publicado: (2022)

Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
por: Bellido, M., et al.
Publicado: (2012)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients
por: Capecchi, Marco, et al.
Publicado: (2023)

Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19
por: Martinelli, Ida, et al.
Publicado: (2021)

Thrombotic Complications Associated with Immune Checkpoint Inhibitors
por: Wang, Tzu-Fei, et al.
Publicado: (2021)

Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis
por: Artoni, Andrea, et al.
Publicado: (2017)

Comparison of adverse drug reactions among four COVID‐19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites
por: Abbattista, Maria, et al.
Publicado: (2021)

Where do we stand with antithrombotic prophylaxis in patients with COVID-19?
por: Ciavarella, Alessandro, et al.
Publicado: (2020)

Covid-19 vaccination in patients with immune-mediated thrombotic thrombocytopenic purpura: a single-referral center experience
por: Trisolini, Silvia Maria, et al.
Publicado: (2022)

Carfilzomib‐induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study
por: Kozlowski, Piotr, et al.
Publicado: (2020)

Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
por: Abdelsamia, Mahmoud, et al.
Publicado: (2023)

Prognostic value of the hemolysis index in patients with significant hemolysis
por: Cortés, Diego O, et al.
Publicado: (2015)

Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature
por: Capecchi, Marco, et al.
Publicado: (2021)

INTERFERENCE WITH IMMUNE HEMOLYSIS BY GLYCOPROTEIN ANTIGENS
por: Arquilla, E. R., et al.
Publicado: (1964)

FUNCTION OF COMPONENTS OF COMPLEMENT IN IMMUNE HEMOLYSIS
por: Pillemer, L., et al.
Publicado: (1942)

Dramatic presentation of acquired thrombotic thrombocytopenic purpura associated with COVID-19
por: Capecchi, Marco, et al.
Publicado: (2020)

Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura
por: Bae, Sung Hwa, et al.
Publicado: (2022)

Thrombotic and Hypercoagulability Complications of COVID-19: An Update
por: Shibeeb, Sapha, et al.
Publicado: (2021)

COVID-19 Associated Coagulopathy and Thrombotic Complications
por: Mezalek, Zoubida Tazi, et al.
Publicado: (2020)

Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case–control study
por: Ferrari, Barbara, et al.
Publicado: (2014)

In vitro Inhibition of Canine Complement‐Mediated Hemolysis
por: Hernandez, D.M., et al.
Publicado: (2017)

Plasma Exchange in a Patient with Immune Thrombocytopenia Associated with Antiphospholipid Syndrome Hospitalized for COVID-19
por: Boggio, Federico, et al.
Publicado: (2022)

Management of Thrombotic Complications in COVID-19: An Update
por: Hajra, Adrija, et al.
Publicado: (2020)

Thrombotic Complications in Children with COVID-19 and MIS-C
por: Kumar, Riten, et al.
Publicado: (2023)

Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
por: Cilla, Nicolas, et al.
Publicado: (2020)

Hemolysis in a Patient during Hemodialysis
por: Taghavi, Maxime, et al.
Publicado: (2021)

Non-immune Hemolysis in Gaucher Disease and Review of the Literature
por: Hershkop, Eliyakim, et al.
Publicado: (2021)

THE REACTION MECHANISM OF HUMAN C5 IN IMMUNE HEMOLYSIS
por: Cooper, Neil R., et al.
Publicado: (1970)

KINETIC STUDIES ON IMMUNE HEMOLYSIS : I. A METHOD
por: Mayer, Manfred M., et al.
Publicado: (1948)

THE EFFECT OF RHEUMATOID FACTORS AND OF ANTIGLOBULINS ON IMMUNE HEMOLYSIS IN VIVO
por: Kaplan, Manuel E., et al.
Publicado: (1963)

Severe drug-induced immune hemolysis due to ceftriaxone
por: Dara, Ravi C., et al.
Publicado: (2020)

Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Thrombotic complications of COVID-19
por: Avila, Jacob, et al.
Publicado: (2021)

Peripartum cardiomyopathy and thrombotic complications
por: Aksu, Ugur, et al.
Publicado: (2019)

Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment
por: Gąsecka, Aleksandra, et al.
Publicado: (2020)

Effect of dilution of canine blood samples on the specificity of saline agglutination tests for immune‐mediated hemolysis
por: Sun, Prudence L., et al.
Publicado: (2020)

ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Bonnez, Quintijn, et al.
Publicado: (2023)

MECHANISM OF HEMOLYSIS BY COMPLEMENT : I. COMPLEMENT FIXATION AS AN ESSENTIAL PRELIMINARY TO HEMOLYSIS.
por: Eagle, Harry, et al.
Publicado: (1929)

Cannot write session to /tmp/vufind_sessions/sess_67ahn88bj0a43t218d1hdpfe2c